FDA granted Fast Track designation for IK-930, a novel TEAD inhibitor targeting the Hippo signaling pathway, in patients with unresectable NF2-deficient malignant pleural mesothelioma.
Cullinan Oncology Inc. and Taiho Pharmaceutical Co. Ltd. completed their agreement to collaborate on the U.S. development of CLN-081/TAS6417, a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer (The Cancer Letter, May 13, 2022).Â
FDA announced it will issue marketing denial orders to all JUUL e-cigarette products. The products must be removed from shelves across the country or risk enforcement action, as FDA has ruled they do not meet the public health standard required to be authorized for sale.
As she was interviewing for the director’s job at the George Washington Cancer Center, Julie E. Bauman was asked what her biggest fear would be.
NCI and Cancer Research UK have awarded $100 million in total funding through the Cancer Grand Challenges program, supporting research into solid tumors in children, cachexia, extrachromosomal DNA, and tumor development.
In the next phase of the Cancer Moonshot, NCI will focus on investing in the development and testing of new modalities, including multi-cancer early detection assays, and fostering diversity in oncology, NCI Acting Director Douglas R. Lowy said at a joint meeting of the Board Of Scientific Advisors and the National Cancer Advisory Board.
Pavan Reddy was named director of the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine. He will lead oncology services, research, and strategic growth at Baylor St. Luke’s Medical Center.
Philip Okala was named system president at City of Hope.Â
Stephen M. Ansell was named enterprise deputy director and senior deputy director, Midwest, of the Mayo Clinic Cancer Center.
Folakemi Odedina was named enterprise deputy director of community outreach and engagement at Mayo Clinic Cancer Center.
